Kruger Products Prices Senior Unsecured Notes GlobeNewswire December 03, 2025 NOT FOR DISTRIBUTION TO NEWSWIRE SERVICES IN U.S. OR FOR DISSEMINATION IN U.S. MISSISSAUGA, Ontario, Dec. 03, 2025 (GLOBE NEWSWIRE) — KP Tissue Inc. (KPT) (TSX: KPT) announced today that Kruger Products Inc. (“KPI”) has, pursuant to an underwriting agreement entered into today, agreed to […]
Dual-action technology delivers broad-spectrum disease control and resistance management-helping Golf Superintendents keep greens pristine and playable. Sipcam Agro USAproudly announces the launch ofCarve™ Xtra, a next-generation turf fungicide engineered to meet the rigorous demands of golf course disease management. Developed with golf superintendents and turf managers in mind, Carve™ Xtra deliversbroad-spectrum control,preventive and curative activity,
(AUST:MSB.AX),(NASDAQ:MESO), NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at the Piper Sandler 37th Annual Healthcare Conference in New York on December 2-4, 2025. Silviu Itescu, Chief Executive of Mesoblast, is scheduled for a fireside chat at 12.00
(NASDAQ:BIIB), Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer's disease by up to 8.3 years in low-amyloid group who started treatment at an early stage New safety and efficacy data presented at scientific symposium on subcutaneous formulation for LEQEMBI initiation treatment, which is under regulatory review
Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer's diseaseby up to 8.3 years in low-amyloid group who started treatment at an early stage New safety and efficacy data presented at scientific symposium on subcutaneous formulation for LEQEMBI initiation treatment, which is under regulatory review in the
Mesoblast Participation at Piper Sandler Conference GlobeNewswire December 03, 2025 NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced its participation at the Piper Sandler 37th Annual Healthcare Conference in New York on December 2-4, 2025. Silviu Itescu, Chief Executive of
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 GlobeNewswire December 03, 2025 Long-term LEQEMBI treatment suggests potential to delay disease progression from Mild Cognitive Impairment (MCI) to moderate Alzheimer's disease by up to 8.3
Sarah Leeper, President of California American Water, issued the following statement in response to the grade of D+ for drinking water in the American Society of Civil Engineers' (ASCE) 2025 Report Card for California's Infrastructure: https://mma.prnewswire.com/media/2835737/California_American_Water_Logo.jpg “At California American Water, our commitment goes beyond maintaining pipes and pumps-it's about safeguarding the health, safety, and prosperity
(NYSE:AGL), NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of agilon health, inc. (NYSE: AGL) resulting from allegations that agilon health may have issued materially misleading business information to the investing public. SO WHAT: If
AGL Investor News: If You Have Suffered Losses in agilon health, inc. (NYSE: AGL), You Are Encouraged to Contact The Rosen Law Firm About Your Rights GlobeNewswire December 03, 2025 NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on